SachsForum
  SachsForum
  • EVENTS:
    • Upcoming Events >
      • 1st ENIF Forum
      • 19th ELSF Forum
    • Recent Events >
      • 9th NIF >
        • POST 9th NIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 11th OIF >
        • POST 11th OIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 25th BEF >
        • POST 25th BEF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 12th HTIF >
        • POST 12th HTIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Supporters
      • 1st EBOIF >
        • POST 1st EBOIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 18th ELSF >
        • POST 18th ELSF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 8th NIF >
        • POST 8th NIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 1st BOIF >
        • POST 1st BOIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 24th BEF >
        • POST 24th BEF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 11th HTIF >
        • POST 11th HTIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Supporters
      • 10th OIF >
        • POST 10th OIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 17th ELSF >
        • POST 17th ELSF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 5th EHTF >
        • POST 5th EHTF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 7th NIF >
        • 7th NIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 23rd BEF >
        • POST 23rd BEF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 10th HTIF >
        • POST 10th HTIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 9th IOIF >
        • POST 9th IOIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 4th EHTF >
        • POST 4th EHTF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 16th ELSF >
        • POST 16th ELSF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 6th NIF >
        • POST 6th NIF
        • Participants >
          • Attendees
          • Investors
          • Showcases
          • Exhibitors
          • Sponsors
          • Supporters
      • 2nd SBISS >
        • POST 2nd SBISS
        • Participants >
          • Attendees
          • Showcases
          • Sponsors
      • 9th HTIF >
        • POST 9th HTIF
        • Participants >
          • Investors
          • Attendees
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 22nd BEF >
        • POST 22nd BEF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 1st SBISS >
        • POST 1st SBISS
        • Participants >
          • Attendees
          • Showcases
          • Sponsors
      • 8th IOIF >
        • POST 8th IOIF
        • Participants >
          • Attendees
          • Investors
          • Showcases
          • Sponsors
          • Supporters
      • 5th NIF Forum >
        • POST 5th NIF Forum
        • Participants >
          • Attendees
          • Investors
          • Showcases
          • Sponsors
          • Supporters
      • 15th ELSF Forum >
        • POST 15th ELSF Forum
        • Participants >
          • Attendees
          • Investors
          • Showcases
          • Sponsors
          • Supporters
      • 3rd EHTF Forum >
        • POST 3rd EHTF Forum
        • Participants >
          • Attendees
          • Investors
          • Showcases
          • Sponsors
          • Supporters
      • 21st BEF Forum >
        • POST 21st BEF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 8th HTIF >
        • POST 8th HTIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 7th IOIF >
        • POST 7th IOIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 14th ELSF >
        • Post 14th ELSF Forum
        • Recordings
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 2nd EHTF >
        • Post 2nd EHTF Forum
        • Recordings
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 4th NIF >
        • Post 4th NIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Supporters
      • 20th BEF >
        • POST 20th BEF Forum
        • Recordings
        • Participants >
          • Presenting Companies
          • Attendees
          • Investors
          • Sponsors
          • Supporters
      • NCIF >
        • POST NCIF Forum
        • Recordings
        • Participants >
          • Presenting Companies
          • Attendees
          • Investors
          • Sponsors
          • Supporters
      • 6th IOIF >
        • POST 6th IOIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenting companies
          • Sponsors & Supporters
      • 13th ELSF >
        • POST 13th ELSF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenting Companies
          • Rising Stars
          • Exhibitors
          • Sponsors
          • Supporters
      • EHTF >
        • POST EHTF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenting Companies
          • Rising Stars
          • Sponsors
          • Supporters
      • 3rd NIF >
        • POST 3rd NIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenting Companies
          • Sponsors & Supporters
      • 19th BEF >
        • POST 19th BEF Forum
        • Participants >
          • Attendees
          • Investors & Analysts
          • Presenting Companies
          • Rising Stars
          • Exhibitors
          • Sponsors
          • Supporters
      • 7th HTIF >
        • POST 7th HTIF Forum
        • Participants >
          • Attendees
          • Investors & Analysts
          • Presenting Companies
          • Rising Stars
          • Exhibitors
          • Sponsors
          • Supporters
      • 5th IOBDLI >
        • POST 5th IOBDLI
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsor & Supporters
      • 12th ELSCEO >
        • POST 12th ELSCEO
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors
          • Sponsors
          • Supporters
          • Rising Stars
      • GFI LS >
        • POST GFI LS
        • Participants >
          • Speakers
          • Israeli Companies
          • Sponsors
          • Supporters
      • 2nd NIF >
        • POST 2nd NIF
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors
          • Sponsors & Supporters
      • 18th BEF >
        • POST 18th BEF
        • Participants >
          • Attendees
          • Speakers
          • Presenting Companies
          • Exhibitors
          • Investors & Analysts
          • Sponsors
          • Supporters
          • Seeds
      • 6th MTDH >
        • POST 6th MTDH
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors & Analysts
          • Sponsors
          • Supporters
          • Seeds
      • 4th IOBDLI >
        • POST 4th IOBDLI Forum
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors
          • Sponsors & Supporters
      • 11th ELSCEO >
        • POST 11th ELSCEO
        • Participants >
          • Attendees
          • Investors & Advisory
          • Presenting Companies
          • Sponsors & Supporters
      • 1st NIF >
        • POST 1st NIF
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors
          • Sponsors & Supporters
      • 17th BEF >
        • POST 17th BEF
        • Participants >
          • Attendees
          • Exhibitors
          • Investors
          • Presenting Companies
          • Sponsors & Supporters
      • 5th MTDH >
        • Post 5th MT&DH
        • Participants >
          • Attendees
          • Exhibitors
          • Investors
          • Presenting Companies
          • Sponsors & Supporters
      • 3rd IOBDLI >
        • 3rd Immuno-Oncology BD&L and Investment Forum >
          • Post IOBDLI Forum 2017
          • Leave Feedback
          • Participants >
            • Attendees
            • Investors & Advisory
            • Presenting Companies
            • Sponsors & Supporters
          • Agenda and Guide
      • 1st BCUSA >
        • POST BCUSA Forum
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors & Analysts
          • Supporters
      • 5th CBPI >
        • 5th Annual Cancer BioPartnering & Investment Forum >
          • Post CBPI Forum 2017
          • Leave Feedback
          • Participants >
            • Attendees
            • Investors and Advisory
            • Presenting Companies
            • Sponsors & Supporters
          • Agenda & Guide
      • 2nd NBPI >
        • 2nd Annual Neuroscience BioPartnering & Investment Forum >
          • Post NBPI Forum 2017
          • Leave Feedback
          • Participants >
            • Attendees
            • Investors and Advisory
            • Presenting Companies
            • Sponsors & Supporters
          • Agenda & Guide
          • 1st Annual Neuroscience BioPartnering & Investment Forum >
            • Agenda
            • Attendees
            • One-2-One Networking
            • Presenting Companies
            • Speakers
            • Supporters
            • Venue
            • Accommodation
      • 10th ELSCEO >
        • 10th Annual European Life Sciences CEO Forum & Exhibition >
          • Post ELSCEO Forum 2017
          • Leave Feedback
          • Participants >
            • Attendees
            • Exhibitors
            • Investors & Advisory
            • Presenting Companies
          • Sponsors & Supporters
          • Venue
          • Accommodation
      • 16th BEF >
        • 16th Annual Biotech in Europe Investor Forum >
          • Post Basel Forum 2016
          • Participants >
            • Attendees
            • Exhibitors
            • Investors & Advisory
            • Presenting Companies
            • Speakers
          • Sponsors
          • Supporters
          • Accommodation
          • Venue
      • 4th MT&DH >
        • 4th Annual MedTech & Digital Health Forum >
          • Post Basel Forum 2016
          • Participants >
            • Attendees
            • Exhibitors
            • Investors & Advisory
            • Presenting Companies
            • Speakers
          • Sponsors
          • Supporters
          • Accommodation
          • Venue
      • Events Archive >
        • 2nd Immuno-Oncology BD&L and Investment Forum >
          • Agenda
          • Attendees
          • Presenting Companies
          • Sponsors
          • Supporters
          • Venue
          • Accommodation
        • 9th Annual European Life Science CEO Forum & Exhibition >
          • Agenda
          • Attending Companies
          • PresentingCompanies
          • Sponsors
          • Supporters
          • Venue
          • Accommodation
        • 4th Annual Cancer BioPartnering & Investment Forum >
          • Agenda
          • Attendees
          • One-2-One Networking
          • Presenting Companies
          • Speakers
          • Sponsors
          • Supporters
          • Venue
          • Accommodation
        • 15th Annual Biotech in Europe Forum >
          • Post Forum Site
          • Participants >
            • Attendees
            • Exhibitors
            • Financial/Advisory/Investors Attending
            • Presenting Companies
            • Speakers
            • Sponsors
            • Supporters
          • Picture Gallery
          • Webcasts
        • 3rd Annual MedTech & Digital Health Forum >
          • Post Forum Site
          • Participants >
            • Attendees
            • Financial/Advisory/Investors Attending
            • Presenting Companies
            • Speakers
            • Sponsors
            • Supporters
          • Picture Gallery
          • Webcasts
        • 1st Immuno-Oncology: BD&L and Investment Forum >
          • About the Forum
          • Picture Gallery
          • Downloadable
          • Leave a Feedback
        • 8th Annual European Life Science CEO Forum & Exhbition
        • 3rd Annual Cancer BioPartnering & Investment Forum
        • Earlier Events
  • ENIF
    • 1st Annual European Neuroscience Innovation Forum >
      • About 1st ENIF Forum
      • Agenda
      • Registration >
        • Regular registration
        • Complimentary registration
      • Attendees
      • Investors
      • Presenters
      • Sponsors
      • Supporters
      • One-2-One Networking
      • Venue
      • Accommodation
  • ELSF
    • 19th Annual European Life Scienes CEO Forum >
      • About 19th ELSF Forum
      • Agenda
      • Registration >
        • Regular registration
        • Complimentary registration
      • Attendees
      • Investors
      • Presenters
      • Sponsors
      • Supporters
      • One-2-One Networking
      • Venue
      • Accommodation
    • Post 18th ELSF Forum
    • Post 17th ELSF Forum
    • Post 16th ELSF Forum
    • Post 15th ELSF Forum
    • Post 14th ELSF Forum
    • Post 13th ELSF Forum
  • OCIF
    • 2nd Annual Obesity & Cardiometabolic Innovation Forum >
      • About 2nd OCIF Forum
      • Registration >
        • Regular Registration
        • Complimentary Registration
      • One-2-One Networking
      • Venue
      • Accommodation
    • Post 1st BOIF Forum
  • EBOIF
    • Post 1st EBOIF Forum
  • HTIF
    • Post 12th HTIF Forum
    • Post 11th HTIF Forum
    • Post 10th HTIF Forum
    • Post 9th HTIF Forum
    • Post 8th HTIF Forum
    • Post 7th HTIF Forum
  • BEF
    • Post 25th BEF Forum
    • Post 24th BEF Forum
    • Post 23rd BEF Forum
    • Post 22nd BEF Forum
    • Post 21st BEF Forum
    • Post 20th BEF Forum
    • Post 19th BEF Forum
  • OIF
    • Post 11th OIF
    • Post 10th OIF
    • Post 9th IOIF
    • Post 8th IOIF
    • Post 7th IOIF
    • Post 6th IOIF
  • NIF
    • Post 9th NIF
    • Post 8th NIF Forum
    • Post 7th NIF Forum
    • Post 6th NIF Forum
    • Post 5th NIF Forum
    • Post 4th NIF Forum
    • Post 3rd NIF Forum
  • ABOUT US

1ST ANNUAL EUROPEAN NEUROSCIENCE INNOVATION FORUM
FOR BUSINESS DEVELOPMENT, LICENSING & INVESTMENT
3RD MARCH 2026 | HILTON ZURICH AIRPORT HOTEL | SWITZERLAND


PRESENTERS AT THE #Sachs​_ENIF FORUM

ABOUT 1st_ENIF
> AGENDA
> REGISTRATION​
> ATTENDEES
> INVESTORS
> PRESENTERS
​
> SPONSORS​
> SUPPORTERS​
> NETWORKING​
> VENUE
> ACCOMMODATION

> ABOUT USA EDITION IN 2025

20-minute presenters

Galimedix Therapeutics, Inc.

"Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies for serious brain and retinal diseases.  

Lead program, GAL-101 (eye drops), is in a Phase 2 trial for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration (dAMD). An oral formulation of GAL-101 has successfully completed Phase 1 testing and shown to be safe, well tolerated, and effectively crosses the blood-brain barrier. Target engagement could be shown. Phase 2 trials in Alzheimer’s (oral) and glaucoma (eye drops) are planned.  A next-generation compound, GAL-301, is in pre-clinical testing.

Galimedix is looking for crossover financing to progress GAL-101 to clinical proof of concept in Alzheimer´s disease and to advance its earlier-stage programs ahead of a planned US IPO.

Galimedix has signed a licensing and equity deal with Théa Open Innovation for co-development and commercial rights to GAL-101 in ophthalmology, excluding APAC and CIS, and is pursuing additional regional partnerships.
​
Recent highlights include the successful completion of the first-in-human study of the oral version of GAL-101, data presented at CTAD, and the ongoing Phase 2 eDREAM trial in GA, with initial results anticipated within a year.

www.galimedix.com
Picture

IAMA Therapeutics S.r.l.

IAMA Therapeutics is a clinical-stage biopharmaceutical company committed to developing innovative treatments for central nervous system disorders. The company’s lead compound, IAMA-6, is a selective NKCC1 inhibitor designed to restore chloride homeostasis and rebalance GABAergic signaling in conditions such as autism, epilepsy, and other neurodevelopmental disorders.

With a successfully completed phase 1 study, IAMA-6 is progressing to Phase 2 proof of concept studies.

www.iamatherapeutics.com
Picture

10-minute presenters

Amporin Pharmaceuticals AG

Amporin is developing the first class of oral drugs that could stop and reverse over 50 deadly degenerative diseases, uniquely by repairing the holes in cell membranes formed by toxic misfolded protein oligomers, allowing diseased cells to fully recover and restore homeostasis. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson's disease.​

www.amporin.com
Picture

Amyl Therapeutics SRL

Amyl Tx successfully develops a fusion protein combining the efficacy of multiple monoclonals without their safety limitations, with enhanced brain exposure, for the treatment of Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases.
​​
www.amyltx.com
Picture

Aprecia Pharmaceuticals, LLC

Founded in 2003, Aprecia Pharmaceuticals is a pioneering force in additive manufacturing, dedicated to revolutionizing drug delivery through three-dimensional printing (3DP) technology. With over 20 years of innovation, Aprecia remains the first and only 3DP company in the world to achieve regulatory product approval, bringing groundbreaking products like Spiritam® to market. Boasting 126 granted patents and 52 pending, Aprecia’s commitment to innovation is unmatched. Aprecia is led by a team of seasoned pharmaceutical experts and continues to develop unique pharmaceutical products through global partnerships, leveraging technology originally developed at MIT. Our commitment to quality and regulatory compliance is reflected in our exemplary track record and partnership with the FDA through the product approval process and Emerging Technology Program (ETP).​​
​
www.aprecia.com
Picture

Curlim

Curlim is a late stage preclinical  biotech company developing an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules. First applications target hereditary peripheral neuropathies and neurodegenerative diseases.

Lead indication is CMT1a, the most common hereditary neuropathy, causing lifelong progressive motor disorders beginning in childhood

At present, there is no pharmacological treatment for nervous disorders known as peripheral neuropathies. Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy (HPN). Therapeutic strategies remain very limited and do not address the cause of the disease, but mainly its symptoms. This lack of pharmacological treatment is particularly dramatic in the case of hereditary peripheral neuropathies, as they are diffuse and often manifest very early in the patient's life and persist throughout their lifetime.

Our solution has been developed by LImoges labs (neuro and sciences) and consists of a Platform technology. The platform is a novel cationic beta-cyclodextrin crystalline-nanocrystal (B-CD/CNC) nanocarrier system for improved solubility, bioavailability, and cellular penetration of APIs.

Our compund CLM001 Targets Oxidative Stress, Heavily Implicated in Peripheral Neuropathies.

CLM001 obtained unprecedented and spectacular therapeutic effects demonstrated on 2 CMT1A animal models showing anti-inflammatory, antioxidant, and remyelinating effects, with no toxicity signals

CLM001 shows a significant rescue in the nerve function. When treated for a total of 12 weeks, CLM001 significantly improved balance/speed and increased the nerve conductivity

In parallel, Primary and secondary modes of action have been characterized.

From a regulatory point of view, Orphan Drug Designation has been granted both by EMA and by FDA.

CMC is finalized and next development stage will be the launch of pre-clinical toxicology study.

www.curlim.eu
Picture

Evox Therapeutics Ltd.

Evox Therapeutics is developing a differentiated pipeline of gene editing medicines addressing severe unmet medical need in genetically driven neurodegenerative diseases, including targeting MSH3 for Huntington's disease and ATXN2 for ALS. By leveraging a proprietary next-generation gene editing modality delivered in a natural non-viral delivery vehicle, we are able to knock out genetically validated disease-causing genes and thereby unlock the clinical and commercial opportunity for genome editing in the central nervous system. We have selected development candidates for our Huntington’s and ALS programs, completed NHP biodistribution studies showing excellent exposure to key brain regions, and obtained regulatory endorsement from the UK regulator the MHRA for our non-clinical, clinical and CMC strategy. Our HD and ALS programs are currently in CTA-enabling studies and with our proprietary manufacturing process currently in tech transfer to a CDMO we have clear line of sight to first-in-human in Huntington’s disease by 2027 with several key milestones along the way​.

​www.evoxtherapeutics.com
Picture

Macomics Ltd.

Macomics is a macrophage drug discovery company, passionate about the therapeutic potential of targeting macrophages for better therapies. We are developing novel treatments for diseases where current therapeutics are severely limited or ineffective.

Macomics’ ENIGMAC drug discovery platform is designed to discover therapeutic targets and unlock disease specific target biology. The platform enables identification and validation of novel targets and provides a translationally relevant path to the clinic through the development of more physiologically relevant human models combined with proprietary gene editing technology. 

Already proven in first-in-class target validation is oncology, ENIGMAC is a proprietary technology developed to produce gene editable microglia as well as macrophages. The platform can knock in or knock out genes of interest via CRISPRa or CRISPRi expression in iPSC derived cells, unlocking the opportunity for new target discovery informed by human data.

For neurology disease-related drug discovery, Macomics has focused on lipid uptake effects on microglia to mimic inflammation combined with lipid loading. Now tested in several readouts including lysosomal function, cytokine release and phagocytosis it has designed a fully validated in vitro system.

www.macomics.com
Picture

Reconnect Labs AG

Reconnect Labs is a Swiss, clinical stage biotech company developing rapid-acting precision therapeutics for interventional precision psychiatry with the potential to transform the treatment landscape for substance use disorders, post-partum depression, PTSD, and insomnia. 

www.reconnect-labs.com
Picture

Vandria SA

Vandria is a clinical-stage biotech company based in Lausanne, Switzerland, developing first-in-class therapies targeting mitochondrial dysfunction to treat age-related diseases. Our lead compound, VNA‑318, is a brain-penetrant mitophagy inducer currently in Phase 1 clinical trials for neurodegenerative conditions. Backed by over $30 million in Series A funding and supported by European innovation grants, Vandria aims to restore cellular resilience and improve health span through mitochondrial science.​

www.vandria.com
Picture

VIRTUAL SHOWCASES

​Ariana Pharma

Profile coming soon...

www.arianapharma.com
Picture

Sachs Associates Switzerland AG
​

​Aeschenvorstadt 4
Basel | CH-4501
​Switzerland
​

Sachs Associates Ltd.

​
​3rd floor, 89-90 Paul Street
London | EC2A 4NE
​United Kingdom


T: +44 203 463 4890
E: [email protected]

© COPYRIGHT 2025. ALL RIGHTS RESERVED.